Christine Zedelmayer, who serves as Senior Vice President and Chief Operating Officer at Equillium (NASDAQ: EQ), completed a block sale of common stock on March 13, 2026. The transaction consisted of 120,312 shares sold for a total proceeds amounting to $300,816. The sales were carried out at a weighted average price of $2.5003 per share, with individual trade prices ranging from $2.50 to $2.515. The disposition was executed under a pre-arranged 10b5-1 trading plan.
On the same calendar day, Zedelmayer executed stock options to acquire 120,312 shares of Equillium common stock at an exercise price of $0.785 per share. The cash required to exercise those options totaled $94,444. After accounting for the sale and the option exercise, Zedelmayer's direct ownership position in Equillium stands at 62,586 shares.
Market data referenced by InvestingPro indicates that Equillium's shares have appreciated more than 207% over the last 12 months. InvestingPro also shows the company's stock trading above its Fair Value estimate and lists Equillium on the platform's Most Overvalued list. The platform further notes that subscribers have access to 13 additional tips about Equillium, including analyses of the company's financial health and valuation measures.
Separately, Equillium has entered into a securities purchase agreement with RA Capital Management that is expected to generate approximately $35 million in gross proceeds. As part of that arrangement, the company intends to issue about 18.9 million shares of common stock at a purchase price of $1.854 per share. According to the terms disclosed, that purchase price reflects the average closing price of Equillium shares over the prior five trading days.
Equillium has also drawn renewed analyst attention. Roth/MKM initiated coverage with a buy rating and set a $12.00 price target, citing the potential of EQ504, an experimental colon-targeted oral pill being developed for ulcerative colitis and now entering Phase 1 trials. The firm referenced a market opportunity valued at over $12 billion for that indication.
Stifel likewise commenced coverage with a buy rating and assigned a $5.00 price target, highlighting the company's pursuit of a novel therapy for inflammatory bowel disease and the broader need for innovation in that therapeutic area. Taken together, the financing and the newly issued research coverage underline both strategic financings and external analyst interest in Equillium's clinical-stage pipeline.
Key developments at a glance
- Insider sale: 120,312 shares sold on March 13, 2026 for $300,816 under a 10b5-1 plan at a weighted average of $2.5003 per share.
- Option exercise: Same day exercise of 120,312 options at $0.785 per share for a total of $94,444; resulting direct ownership is 62,586 shares.
- Corporate financing: Securities purchase agreement with RA Capital Management for roughly $35 million via issuance of about 18.9 million shares at $1.854 each.
Context and market signals
InvestingPro data cited in company materials shows a one-year share-price increase exceeding 207% and places the stock above that service's Fair Value estimate. Analyst initiations from Roth/MKM and Stifel both carry buy ratings, with divergent price targets of $12.00 and $5.00, respectively, and both firms point to the development of treatments targeting inflammatory bowel conditions, including EQ504 entering Phase 1.